HLA-DRBI peptides with specific binding affinity for HLA-DQ molecules: prevention and treatment of rheumatoid arthritis
US5965787A · kind A · utility
26Cited by
0References
8Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 31, 1995 |
| Grant date | Oct 12, 1999 |
| Priority date | — |
| Expiry date | Aug 31, 2015 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed are transgenic mice carrying a human HLA-DQ sgene. The transgenic mice are deficient in mouse H-2 class II molecules. Such mice provide animal model systems to identify peptides useful for preventing or treating rheumatoid arthritis. Also disclosed are methods and materials for treating rheumatoid arthritis, including administration of peptides having specific binding affinity for HLA-DQ molecules expressed in a rheumatoid arthritis patient.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.